Showing results (191-200 of 204) with videos related to
Sort By:
Pageof 21
Journal of the National Comprehensive Cancer Network : JNCCN|March 10, 2017
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017William G Wierda, Andrew D Zelenetz, Leo I Gordon, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2016
Diffuse Large B-Cell Lymphoma Version 1.2016Andrew D Zelenetz, Leo I Gordon, William G Wierda, et al.The New England Journal of Medicine|April 12, 2018
Genetics and Pathogenesis of Diffuse Large B-Cell LymphomaRoland Schmitz, George W Wright, Da Wei Huang, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2023
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023Andrew D Zelenetz, Leo I Gordon, Jeremy S Abramson, et al.Blood|August 28, 2014
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysisAdam M Petrich, Mitul Gandhi, Borko Jovanovic, et al.Blood Advances|August 5, 2025
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysisZachary D Epstein-Peterson, Anath Christopher Lionel, Ashlee Joseph, et al.The Lancet. Haematology|November 26, 2021
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trialJacob D Soumerai, Anthony R Mato, Ahmet Dogan, et al.Science (New York, N.Y.)|February 1, 2024
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127Skye Montoya, Jessie Bourcier, Mark Noviski, et al.Blood|December 10, 2025
CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosisJoseph M Rocco, Joseph H Oved, Rikita J Patel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2020
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective StrategyAnthony R Mato, Lindsey E Roeker, Ryan Jacobs, et al.Pageof 21